Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. BVAXF


Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Comment by javaman12on Oct 30, 2024 3:38pm
28 Views
Post# 36289355

RE:On the other hand the CEO sees a market cap in the billions

RE:On the other hand the CEO sees a market cap in the billions I am hoping that as a former hedge fund manager, Mr. Passin, the CEO may be able to make some convincing arguments with many new potential investors on Friday at the Emerging Growth Conference. 

I will also be keen to listen to find out if anything new is on the table. I believe that we will get a post event viewing of the company's presentation later, on the Emerging Growth, Utube channel.

Although I haven't checked out any of the companies attending that event, perhaps some other Biotec or Pharmaceutical juniors may also be attending. The matter of scale is important to the investment community as well as the speed at which any new drug strategy may bring in some nearer term revenue growth. 

Could a new partnership soon be in the works? Or another licensing deal? 

Now is an excellent time to pick up a lot of new shares when 'profit taking or tired of waiting investors' are selling. But once the company gets a reliable partnership up and going, shareholders will become less quick to unload at these low ball prices!

And any real talk of a Nasdaq listing or other US stock exchange, will also add to any such hesitation. 

Once a listed company on the Nasdaq starts getting some substantial revenue inflows, investors then realize that there may be a real possibility of a take-over bid from big Pharma. At that point even Nasdaq penny shares soon become dollar sized stocks.

On the Nasdaq, penny stocks with the greater potential get the real attention that they richly deserve! They get noticed by those Americans with bigger dollars in their pockets, who move their share price, quickly higher, even on low volume trades!

That's why I say it's up to management to get this ball rolling. This Friday's investment conference is a good place to start!

I have a good amount of these shares already. I may buy a few more as long as these cheap trades continue.

But there is no need for me to be greedy! I will leave a few for others to buy! 

Yeah Christmas might be a good time to begin to see a better move in the share. That would be more timely from the perspective of better priced private placement dollars to refill the company coffers.

But I would rather see Santa come early! Better gifts, may come to us, later! 

Cheap p.p. and lousy priced warrants don't help the share price. 

But I am sure that the CEO knows this and is working hard to get the price moving higher! Stock promotion is also a big part of his job! He does have his own money at stake too!

Don't expect an immediate response from any potential stock buyers after an investment conference takes place. These attendees are usually pretty careful about where they invest. It make take at least a couple of weeks!

After all, everyone has an incredible abundance of choices about where to place their bets! It may take some time to digest all the information available, from such a well advertised, promotional event! 

                                                          All the best! Java

                                                            

<< Previous
Bullboard Posts
Next >>